# Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

> **NCT01673217** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** decitabine
- **BIOLOGICAL:** NY-ESO-1 peptide vaccine
- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **OTHER:** immunohistochemistry staining method
- **OTHER:** liquid chromatography
- **OTHER:** mass spectrometry
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** DNA methylation analysis
- **OTHER:** enzyme-linked immunosorbent assay

## Key facts

- **NCT ID:** NCT01673217
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-10
- **Final completion:** 2013-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673217, "Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01673217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*